BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
6,781€
-10,75%
Echtzeit-Aktienkurs BioCryst Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that…
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst gains 14% most since February after Q1 2023 results
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2023....…
Why BioCryst Pharmaceuticals Stock Is Soaring Today
The biotechs Q1 earnings report contained a number of positives....…
BioCryst Clocks 37.8% Revenue Growth In Q1 On Solid New Patient Growth
read more...…
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million—...…
BioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Pharmaceuticals Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst to Report First Quarter 2023 Financial Results on May 3
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
IN BRIEF: BioPharma Credit invests in BioCryst of up to USD180 million
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst secures five-year credit facility
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the…
Form 8-K BIOCRYST PHARMACEUTICALS For: Mar 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst wins Canadian nod for Orladeyo reimbursement
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Shares of BioCryst Pharmaceuticals Jumped Today
A day after the stock plummeted, it bounced back....…
BioCryst adds 13% to rebound as Needham upgrades; says selloff overdone
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Opening Bell: Nasdaq 100, Dow Jones, Walmart, Palo Alto, Palantir, Coinbase, JD.com, PDD, BioCryst
Die Wall Street startete erst gestern in die neue Handelswoche. Und es war ein verhaltener Start. Der Dow Jones gab…
Opening Bell: Wall Street startet nach Vortagesverlusten freundlich; Fed-Protokoll, Walmart, JD.com, Palo Alto Networks, Palantir, Biocryst, PDD Holdings im Fokus
Die US-Börsen dürften am Mittwoch einen Stabilisierungsversuch starten. Der Dow Jones notiert 30 Minuten vor dem Handelsstart bei 33.182 Punkten,…
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Pharmaceuticals Stock Down 20% After Wider 4Q Loss Reported
BioCryst Pharmaceuticals Stock Down 20% After Wider 4Q Loss Reported...…
Why BioCryst Pharmaceuticals Stock Is Sinking Today
Investors didnt like the drugmakers Q4 update....…
BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2022....…
BioCryst at nine-month low as Q4 bottom-line disappoints
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the…
Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Pharmaceuticals Q4 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Opening Bell: TripAdvisor, Airbnb, Tesla, Biogen, BioCryst
Die US-Inflationsdaten sorgten gestern für eine kleine Berg- und Talfahrt bei den US-Indizes. Am Ende ging der Dow Jones mit…
Opening Bell: Dow Jones startet im Minus; Einzelhandelsumsätze Januar, Biogen, Tripadvisor, Airbnb, Tesla, Biocryst im Fokus
Starke Einzelhandelsumsätze im Januar verunsichern am Mittwoch die Anleger an der Wall Street und drücken die Indizes ins Minus. 30…
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Insiderhandel: President & CEO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 1.038.000$
Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2023-02-01...…
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment…
BioCryst teams up with Swixx to sell Orladeyo in Central, Eastern Europe
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company…
BioCryst drops as sales for hereditary angioedema therapy lag forecasts
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Shares Down After Orladeyo Preliminary Sales, Outlook
BioCryst Shares Down After Orladeyo Preliminary Sales, Outlook...…
Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)—...…
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Insiderhandel: Exec. Director, Finance - PAO verkauft Aktien von BioCryst Pharmaceuticals im Wert von 4.851$
Jones, Michael L. - Vorstand - Tag der Transaktion: 2022-12-15...…
Insiderhandel: Chief Legal Officer verkauft Aktien von BioCryst Pharmaceuticals im Wert von 45.424$
Barnes, Alane P. - Vorstand - Tag der Transaktion: 2022-12-15...…
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH....…
BioCryst strategic interest likely to rise after oral Factor D inhibitor decision - Cowen
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst to discontinue development of drug
Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it…
BioCryst Shares Fall Premarket After BCX9930 Program Scrapped >BCRX
BioCryst Shares Fall Premarket After BCX9930 Program Scrapped >BCRX...…